1
|
Pesch V, Flores-Fernandez JM, Reithofer S, Ma L, Özdüzenciler P, Busch Y, Sriraman A, Wang Y, Amidian S, Kroepel CVM, Müller L, Lien Y, Rudtke O, Frieg B, Schröder GF, Wille H, Tamgüney G. Vaccination with structurally adapted fungal protein fibrils induces immunity to Parkinson's disease. Brain 2024; 147:1644-1652. [PMID: 38428032 PMCID: PMC11068327 DOI: 10.1093/brain/awae061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 01/05/2024] [Accepted: 02/10/2024] [Indexed: 03/03/2024] Open
Abstract
The pathological misfolding and aggregation of soluble α-synuclein into toxic oligomers and insoluble amyloid fibrils causes Parkinson's disease, a progressive age-related neurodegenerative disease for which there is no cure. HET-s is a soluble fungal protein that can form assembled amyloid fibrils in its prion state. We engineered HET-s(218-298) to form four different fibrillar vaccine candidates, each displaying a specific conformational epitope present on the surface of α-synuclein fibrils. Vaccination with these four vaccine candidates prolonged the survival of immunized TgM83+/- mice challenged with α-synuclein fibrils by 8% when injected into the brain to model brain-first Parkinson's disease or by 21% and 22% when injected into the peritoneum or gut wall, respectively, to model body-first Parkinson's disease. Antibodies from fully immunized mice recognized α-synuclein fibrils and brain homogenates from patients with Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Conformation-specific vaccines that mimic epitopes present only on the surface of pathological fibrils but not on soluble monomers, hold great promise for protection against Parkinson's disease, related synucleinopathies and other amyloidogenic protein misfolding disorders.
Collapse
Affiliation(s)
- Verena Pesch
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - José Miguel Flores-Fernandez
- Department of Biochemistry and Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, AB T6G 2M8, Canada
| | - Sara Reithofer
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Liang Ma
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Pelin Özdüzenciler
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Yannick Busch
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Aishwarya Sriraman
- Department of Biochemistry and Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, AB T6G 2M8, Canada
| | - YongLiang Wang
- Department of Biochemistry and Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, AB T6G 2M8, Canada
- Department of Cell Biology and Anatomy, University of Calgary, Calgary, AB T2N 1N4, Canada
| | - Sara Amidian
- Department of Biochemistry and Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, AB T6G 2M8, Canada
| | - Chiara V M Kroepel
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Laura Müller
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Yi Lien
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Olivia Rudtke
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Benedikt Frieg
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Gunnar F Schröder
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
- Physics Department, Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Germany
| | - Holger Wille
- Department of Biochemistry and Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, AB T6G 2M8, Canada
- Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB T6G 2M8, Canada
| | - Gültekin Tamgüney
- Institut für Biologische Informationsprozesse, Strukturbiochemie (IBI-7), Forschungszentrum Jülich, 52425 Jülich, Germany
- Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Germany
| |
Collapse
|
2
|
An der Heiden I, Schiffhorst G, Müller L, Albrecht M, Bartol A, Wiberny S. Examining confidential wholesale margin estimates in European countries for the price negotiation of patented drugs in Germany: a statistical model. Health Econ Rev 2024; 14:27. [PMID: 38607501 PMCID: PMC11010283 DOI: 10.1186/s13561-024-00503-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Accepted: 04/02/2024] [Indexed: 04/13/2024]
Abstract
BACKGROUND Based on the legal framework laid down in section 130b (9) of Book V of the German Social Code, various criteria are relevant for the negotiated price for new patented drugs in Germany. European reference prices (ERPs) are one criterion. The ERP is based on the ex-factory prices (EFPs) of the countries included in the European country basket. However, in some of these countries, the EFP is not published due to confidential wholesale margins. Wholesale margins must therefore be estimated and deducted from purchase prices. In this context literature-based estimates to date do not assume regressive margins with higher pharmaceutical prices. This assumption is questionable and can lead to systematically underestimated country prices, especially for high-priced drugs. Percentage wholesale margins in the majority of European countries develop to a comparable extent regressively with increasing prices. It should therefore be examined (1) whether statistical models can predict the margins of individual countries, in principle and especially for countries where margins are unknown and regressive trends are likely, and (2) to what extent the estimation of margins improves when regressive statistical models are used to estimate margins instead of cross-price averages published in the literature. METHODS Qualitative preliminary research explores the basic wholesale pricing mechanisms in countries with confidential wholesale margins. Wholesale margins for reimbursable drugs were then modeled for regulated European countries. Estimation quality and impact of the model was compared to estimations based on average margins. RESULTS In both regulated countries and in countries with confidential wholesale margins, percentage margins of wholesalers develop regressively as drug prices rise. Regressive courses of margins can be resiliently modeled for the regulated countries using a power distribution with significantly lower mean squared errors in a linear mixed model in comparison to literature-based estimations with country-specific cross-price averages. CONCLUSION If there is reason to believe that margins are regressive, confidential wholesale margins are expected to be better estimated by the power function based on margins of regulated countries than by the published country-specific average margins, reducing significantly inaccurate effects on margin estimations of high-price drugs.
Collapse
Affiliation(s)
| | | | - Laura Müller
- Health Economics, Market Access & Reimbursement, Janssen-Cilag GmbH, Pharmaceutical Companies of Johnson & Johnson, Neuss, Germany
| | | | - Arne Bartol
- Health Economics, Market Access & Reimbursement, Janssen-Cilag GmbH, Pharmaceutical Companies of Johnson & Johnson, Neuss, Germany
| | - Stefanie Wiberny
- Health Economics, Market Access & Reimbursement, Janssen-Cilag GmbH, Pharmaceutical Companies of Johnson & Johnson, Neuss, Germany.
| |
Collapse
|
3
|
Karschuck P, Müller L, Groeben C, Aksoy C, Flegar L, Zacharis A, Baunacke M, Wülfing C, Huber J. [Patient events in German urology: trend towards hybrid formats?]. Urologie 2024; 63:75-82. [PMID: 37566223 DOI: 10.1007/s00120-023-02162-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 06/19/2023] [Indexed: 08/12/2023]
Abstract
BACKGROUND Patient events are an important tool to respond to the increasing need of the public for health information. Through the "patient forum", the German Society of Urology (DGU) is committed to patient information and public relations at its annual congresses. The goal of the study was to evaluate the events from 2017-2019 and to compare them with the first digital patient forum in 2020. MATERIALS AND METHODS Using a two-page standardized questionnaire, we surveyed the visitors of the presence patient forums (presence group = P) of the three annual congresses of the DGU 2017-2019 as well as the users of the digital event 2020 (online group = O). RESULTS We obtained 71 records for 2017-2019 and 18 for 2020. The median age of visitors was 64 years (range 30-89). Males were 66% (P) vs. 83% (O) of participants (p = 0.005). The offer was rated overall as good to very good by both groups, i.e., 1.6 (P) vs. 1.6 (O; p = 0.7) on a scale from 1 to 6 with 1 being the highest rating. In line with the lower interaction in the digital format, the possibility to ask questions was rated worse with 1.5 (P) vs. 2.8 (O; p = 0.003). When asked about the desired future event format, two-thirds of the users of the digital patient forum were in favor of a hybrid event on-site and online. CONCLUSION Patient events are suitable means of communication for the public and are rated well by visitors. In particular, interaction with experts is highly valued. Face-to-face formats are associated with a high logistical effort and high costs, and their reach is limited. In the future, hybrid formats could be a reasonable alternative, as they combine the advantages of online and face-to-face formats.
Collapse
Affiliation(s)
- Philipp Karschuck
- Klinik für Urologie, Philipps-Universität Marburg, Baldingerstraße, 35033, Marburg, Deutschland.
| | - Laura Müller
- Klinik für Urologie, Philipps-Universität Marburg, Baldingerstraße, 35033, Marburg, Deutschland
| | - Christer Groeben
- Klinik für Urologie, Philipps-Universität Marburg, Baldingerstraße, 35033, Marburg, Deutschland
| | - Cem Aksoy
- Klinik für Urologie, Philipps-Universität Marburg, Baldingerstraße, 35033, Marburg, Deutschland
| | - Luka Flegar
- Klinik für Urologie, Philipps-Universität Marburg, Baldingerstraße, 35033, Marburg, Deutschland
| | - Aristeidis Zacharis
- Klinik für Urologie, Philipps-Universität Marburg, Baldingerstraße, 35033, Marburg, Deutschland
| | - Martin Baunacke
- Klinik und Poliklinik für Urologie, Technische Universität Dresden, Dresden, Deutschland
| | | | - Johannes Huber
- Klinik für Urologie, Philipps-Universität Marburg, Baldingerstraße, 35033, Marburg, Deutschland
| |
Collapse
|
4
|
Noseda R, Franchi M, Pagnamenta A, Müller L, Dines AM, Giraudon I, Heyerdahl F, Eyer F, Hovda KE, Liechti ME, Miró Ò, Vallersnes OM, Yates C, Dargan PI, Wood DM, Ceschi A. Determinants of Admission to Critical Care Following Acute Recreational Drug Toxicity: A Euro-DEN Plus Study. J Clin Med 2023; 12:5970. [PMID: 37762912 PMCID: PMC10532086 DOI: 10.3390/jcm12185970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 09/07/2023] [Accepted: 09/12/2023] [Indexed: 09/29/2023] Open
Abstract
This study aimed to characterize patients admitted to critical care following Emergency Department (ED) presentation with acute recreational drug toxicity and to identify determinants of admission to critical care. A retrospective multicenter matched case-control study was conducted by the European Drug Emergency Network Plus (Euro-DEN Plus) over the period 2014-2021. The cases were ED presentations with acute recreational drug toxicity admitted to critical care, the controls consisted of ED presentations with acute recreational drug toxicity medically discharged directly from the ED. The potential determinants of admission to critical care were assessed through multivariable conditional stepwise logistic regression analysis and multiple imputation was used to account for the missing data. From 2014 to 2021, 3448 Euro-DEN Plus presentations involved patients admitted to critical care (76.9% males; mean age 33.2 years; SD 10.9 years). Patient age ≥35 years (as compared to ≤18 years) was a determinant of admission to critical care following acute recreational drug toxicity (adjusted odds ratio, aOR, 1.51, 95% confidence interval, CI, 1.15-1.99), along with polydrug use (aOR 1.39, 95% CI 1.22-1.59), ethanol co-ingestion (aOR 1.44, 95% CI 1.26-1.64), and the use of gamma-hydroxybutyrate/gamma-butyrolactone (GHB/GBL, aOR 3.08, 95% CI 2.66-3.57). Conversely, lower odds of admission to critical care were associated with the use of cocaine (aOR 0.85, 95% CI 0.74-0.99), cannabis (aOR 0.44, 95% CI 0.37-0.52), heroin (aOR 0.80, 95% CI 0.69-0.93), and amphetamine (aOR 0.65, 95% CI 0.54-0.78), as was the arrival to the ED during the night (8 p.m.-8 a.m., aOR 0.88, 95% CI 0.79-0.98). These findings, which deserve confirmation and further investigation, could contribute to a more complete understanding of the decision-making process underlying the admission to critical care of patients with acute recreational drug toxicity.
Collapse
Affiliation(s)
- Roberta Noseda
- Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; (R.N.); (L.M.)
| | - Matteo Franchi
- Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 20126 Milan, Italy;
- National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, 20126 Milan, Italy
| | - Alberto Pagnamenta
- Clinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland;
- Department of Intensive Care, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland
- Division of Pneumology, University of Geneva, 1211 Geneva, Switzerland
| | - Laura Müller
- Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; (R.N.); (L.M.)
| | - Alison M. Dines
- Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London SE1 7EH, UK; (A.M.D.); (P.I.D.); (D.M.W.)
| | - Isabelle Giraudon
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 1249-289 Lisbon, Portugal;
| | - Fridtjof Heyerdahl
- Prehospital Division, Oslo University Hospital, 0424 Oslo, Norway;
- The Norwegian Air Ambulance Foundation, 0184 Oslo, Norway
| | - Florian Eyer
- Department of Clinical Toxicology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany;
| | - Knut Erik Hovda
- The Norwegian CBRNE Centre of Medicine, Oslo University Hospital, 0450 Oslo, Norway;
| | - Matthias E. Liechti
- Clinical Pharmacology and Toxicology, University Hospital and University of Basel, 4056 Basel, Switzerland;
| | - Òscar Miró
- Emergency Department, Hospital Clínic, University of Barcelona, 08036 Catalonia, Spain;
| | - Odd Martin Vallersnes
- Department of General Practice, University of Oslo, 0318 Oslo, Norway;
- Oslo Accident and Emergency Outpatient Clinic, City of Oslo Health Agency, 0182 Oslo, Norway
| | - Christopher Yates
- Emergency Department and Clinical Toxicology Unit, Hospital Universitario Son Espases, 07120 Mallorca, Spain;
| | - Paul I. Dargan
- Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London SE1 7EH, UK; (A.M.D.); (P.I.D.); (D.M.W.)
- Clinical Toxicology, Faculty of Life Sciences and Medicine, King’s College London, London WC2R 2LS, UK
| | - David M. Wood
- Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London SE1 7EH, UK; (A.M.D.); (P.I.D.); (D.M.W.)
- Clinical Toxicology, Faculty of Life Sciences and Medicine, King’s College London, London WC2R 2LS, UK
| | - Alessandro Ceschi
- Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; (R.N.); (L.M.)
- Clinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland;
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland
- Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland
| | | |
Collapse
|
5
|
Graafen D, Müller L, Halfmann MC, Stoehr F, Foerster F, Düber C, Yang Y, Emrich T, Kloeckner R. Soft Reconstruction Kernels Improve HCC Imaging on a Photon-Counting Detector CT. Acad Radiol 2023; 30 Suppl 1:S143-S154. [PMID: 37095047 DOI: 10.1016/j.acra.2023.03.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2023] [Revised: 03/08/2023] [Accepted: 03/20/2023] [Indexed: 04/26/2023]
Abstract
RATIONALE AND OBJECTIVES Hepatocellular carcinoma (HCC) is the only tumor entity that allows non-invasive diagnosis based on imaging without further histological proof. Therefore, excellent image quality is of utmost importance for HCC diagnosis. Novel photon-counting detector (PCD) CT improves image quality via noise reduction and higher spatial resolution, inherently providing spectral information. The aim of this study was to investigate these improvements for HCC imaging with triple-phase liver PCD-CT in a phantom and patient population study focusing on identification of the optimal reconstruction kernel. MATERIALS AND METHODS Phantom experiments were performed to analyze objective quality characteristics of the regular body and quantitative reconstruction kernels, each with four sharpness levels (36-40-44-48). For 24 patients with viable HCC lesions on PCD-CT, virtual monoenergetic images at 50 keV were reconstructed using these kernels. Quantitative image analysis included contrast-to-noise ratio (CNR) and edge sharpness. Three raters performed qualitative analyses evaluating noise, contrast, lesion conspicuity, and overall image quality. RESULTS In all contrast phases, the CNR was highest using the kernels with a sharpness level of 36 (all p < 0.05), with no significant influence on lesion sharpness. Softer reconstruction kernels were also rated better regarding noise and image quality (all p < 0.05). No significant differences were found in image contrast and lesion conspicuity. Comparing body and quantitative kernels with equal sharpness levels, there was no difference in image quality criteria, neither regarding in vitro nor in vivo analysis. CONCLUSION Soft reconstruction kernels yield the best overall quality for the evaluation of HCC in PCD-CT. As the image quality of quantitative kernels with potential for spectral post-processing is not restricted compared to regular body kernels, they should be preferred.
Collapse
Affiliation(s)
- D Graafen
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany (D.G., L.M., M.C.H., F.S., C.D., Y.Y., T.E., R.K.).
| | - L Müller
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany (D.G., L.M., M.C.H., F.S., C.D., Y.Y., T.E., R.K.)
| | - M C Halfmann
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany (D.G., L.M., M.C.H., F.S., C.D., Y.Y., T.E., R.K.); German Center for Cardiovascular Research (DZHK), Partner-Site Rhine-Main, Mainz, Germany (M.C.H., T.E.)
| | - F Stoehr
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany (D.G., L.M., M.C.H., F.S., C.D., Y.Y., T.E., R.K.)
| | - F Foerster
- Department of Medicine I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany (F.F.)
| | - C Düber
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany (D.G., L.M., M.C.H., F.S., C.D., Y.Y., T.E., R.K.)
| | - Y Yang
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany (D.G., L.M., M.C.H., F.S., C.D., Y.Y., T.E., R.K.)
| | - T Emrich
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany (D.G., L.M., M.C.H., F.S., C.D., Y.Y., T.E., R.K.); German Center for Cardiovascular Research (DZHK), Partner-Site Rhine-Main, Mainz, Germany (M.C.H., T.E.); Division of Cardiovascular Imaging, Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC (T.E.)
| | - R Kloeckner
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany (D.G., L.M., M.C.H., F.S., C.D., Y.Y., T.E., R.K.)
| |
Collapse
|
6
|
Müller L, Rosenbaum C, Rump A, Grimm M, Klammt F, Kleinwort A, Busemann A, Weitschies W. Determination of Mucoadhesion of Polyvinyl Alcohol Films to Human Intestinal Tissue. Pharmaceutics 2023; 15:1740. [PMID: 37376191 DOI: 10.3390/pharmaceutics15061740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 06/12/2023] [Accepted: 06/13/2023] [Indexed: 06/29/2023] Open
Abstract
The absorption of drugs with narrow absorption windows in the upper small intestine can be improved with a mucoadhesive drug delivery system such as enteric films. To predict the mucoadhesive behaviour in vivo, suitable in vitro or ex vivo methods can be performed. In this study, the influence of tissue storage and sampling site on the mucoadhesion of polyvinyl alcohol film to human small intestinal mucosa was investigated. Tissue from twelve human subjects was used to determine adhesion using a tensile strength method. Thawing of tissue frozen at -20 °C resulted in a significantly higher work of adhesion (p = 0.0005) when a low contact force was applied for one minute, whereas the maximum detachment force was not affected. When the contact force and time were increased, no differences were found for thawed tissue compared to fresh tissue. No change in adhesion was observed depending on the sampling location. Initial results from a comparison of adhesion to porcine and human mucosa suggest that the tissues are equivalent.
Collapse
Affiliation(s)
- Laura Müller
- Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| | - Christoph Rosenbaum
- Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| | - Adrian Rump
- Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| | - Michael Grimm
- Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| | - Friederike Klammt
- Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| | - Annabel Kleinwort
- Department of General, Visceral, Thoracic and Vascular Surgery, Greifswald University Medicine, Ferdinand-Sauerbruch-Str., 17457 Greifswald, Germany
| | - Alexandra Busemann
- Department of General, Visceral, Thoracic and Vascular Surgery, Greifswald University Medicine, Ferdinand-Sauerbruch-Str., 17457 Greifswald, Germany
| | - Werner Weitschies
- Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany
| |
Collapse
|
7
|
Müller L, Kühl M, Kühl SJ. Climate change and health: Changes in student environmental knowledge and awareness due to the implementation of a mandatory elective at the Medical Faculty of Ulm? GMS J Med Educ 2023; 40:Doc32. [PMID: 37377568 PMCID: PMC10291350 DOI: 10.3205/zma001614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 01/15/2022] [Revised: 07/21/2022] [Accepted: 08/09/2022] [Indexed: 06/29/2023]
Abstract
Background and objectives According to the World Health Organization, climate change constitutes the single greatest threat to human health. However, the health care system contributes to climate change worldwide through its high CO2 emissions. In order to make future physicians more aware of this issue and to expand medical education to include climate-related aspects, the mandatory 28 academic hours elective "Climate Change and Health" for students of human medicine in the preclinical study stage was implemented at the Medical Faculty of Ulm in the 2020/21 winter semester. Our accompanying study investigated 1. in what form the topic of climate change can be successfully integrated into the study of human medicine in a manner that includes student opinions and2. whether being required to take an elective on the topic led to changes in student environmental knowledge and awareness. Methodology Personal individual interviews were conducted with all n=11 students after the course in a pilot that was carried out in the 2020/21 winter semester to determine course feasibility and student acceptance. The students were also able to evaluate the course using an evaluation form and were asked to complete a questionnaire on their environmental knowledge and awareness before and after the course. The course was revised on the basis of the results and offered again in the 2021 summer semester with an intervention group (n=16, participation in the mandatory elective) and a comparison group (n=25, no participation in the mandatory elective). The intervention group was asked to evaluate the course on the evaluation form. Both groups completed the environmental questionnaire at the same time. Results The positive feedback from students for both semesters indicates a good feasibility and acceptance of the course. Student environmental knowledge was increased in both semesters. However, there were only few observable changes in student environmental awareness. Conclusion This paper illustrates how the topic of climate change and health can be embedded into medical studies. The students considered climate change an important topic and drew added value from the course for their future work in healthcare. The study shows that knowledge transfer at the university level is an effective way to educate the young generation on climate change and its impacts.
Collapse
Affiliation(s)
- Laura Müller
- University of Ulm, Medical Faculty, Institute of Biochemistry and Molecular Biology, Ulm, Germany
| | - Michael Kühl
- University of Ulm, Medical Faculty, Institute of Biochemistry and Molecular Biology, Ulm, Germany
| | - Susanne J. Kühl
- University of Ulm, Medical Faculty, Institute of Biochemistry and Molecular Biology, Ulm, Germany
| |
Collapse
|
8
|
Haas H, Müller L, Speck T, Michel MS, Huber J. [Structure of outpatient urology care in Germany]. Urologie 2023; 62:503-509. [PMID: 36894689 PMCID: PMC10160173 DOI: 10.1007/s00120-023-02048-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 02/02/2023] [Indexed: 03/11/2023]
Abstract
BACKGROUND Although urological specialist practices are central pillars of outpatient care, there is a lack of current data on the care structure of these practices. A description of the structures in large cities versus rural areas as well as gender effects and generational differences is needed not only as a baseline measure for further studies. MATERIALS AND METHODS The survey includes data from the physician directory of the Stiftung Gesundheit as well as from the German Medical Association and the Federal Statistical Office. Colleagues were divided into subgroups. Based on the different subgroup sizes, statements about the care structure of outpatient urology in Germany can be made. RESULTS While the majority of urologists in larger cities work in professional practice groups and care for fewer patients on average, in rural areas there is a particularly high proportion of individual practices with more inhabitants to be cared for per urologist. Female urologists work more frequently in the context of inpatient care. When female urology specialists choose to establish themselves, they are more likely to do so in practice groups and in urban areas. In addition, there is a shift in gender distribution: the younger the age subgroup considered, the higher the proportion of female urologists among all colleagues. CONCLUSIONS This study is the first to describe the current structure of outpatient urology care in Germany. Future trends are already emerging that will significantly influence our way of working and the care of patients in the coming years.
Collapse
Affiliation(s)
- Helmut Haas
- Urologische Stiftung Gesundheit gGmbH, Düsseldorf, Deutschland
| | - Laura Müller
- Klinik für Urologie, Philipps-Universität Marburg, 35043, Marburg, Deutschland.
| | | | - Maurice Stephan Michel
- Klinik für Urologie und Urochirurgie, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Deutschland
| | - Johannes Huber
- Klinik für Urologie, Philipps-Universität Marburg, 35043, Marburg, Deutschland
| |
Collapse
|
9
|
Lew AJ, Stifler CA, Tits A, Schmidt CA, Scholl A, Cantamessa A, Müller L, Delaunois Y, Compère P, Ruffoni D, Buehler MJ, Gilbert PUPA. A Molecular-Scale Understanding of Misorientation Toughening in Corals and Seashells. Adv Mater 2023:e2300373. [PMID: 36864010 DOI: 10.1002/adma.202300373] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 02/15/2023] [Indexed: 06/19/2023]
Abstract
Biominerals are organic-mineral composites formed by living organisms. They are the hardest and toughest tissues in those organisms, are often polycrystalline, and their mesostructure (which includes nano- and microscale crystallite size, shape, arrangement, and orientation) can vary dramatically. Marine biominerals may be aragonite, vaterite, or calcite, all calcium carbonate (CaCO3 ) polymorphs, differing in crystal structure. Unexpectedly, diverse CaCO3 biominerals such as coral skeletons and nacre share a similar characteristic: Adjacent crystals are slightly misoriented. This observation is documented quantitatively at the micro- and nanoscales, using polarization-dependent imaging contrast mapping (PIC mapping), and the slight misorientations is consistently between 1° and 40°. Nanoindentation shows that both polycrystalline biominerals and abiotic synthetic spherulites are tougher than single-crystalline geologic aragonite, and molecular dynamics (MD) simulations of bicrystals at the molecular scale reveals that aragonite, vaterite, and calcite exhibit toughness maxima when the bicrystals are misoriented by 10°, 20°, and 30°, respectively, demonstrating that slight misorientation alone can increase fracture toughness. Slight-misorientation-toughening can be harnessed for synthesis of bioinspired materials that only require one material, are not limited to specific top-down architecture, and are easily achieved by self-assembly of organic molecules (e.g., aspirin, chocolate), polymers, metals, and ceramics well beyond biominerals.
Collapse
Affiliation(s)
- Andrew J Lew
- Laboratory for Atomistic and Molecular Mechanics (LAMM), Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, MA, 02139, USA
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, MA, 02139, USA
| | - Cayla A Stifler
- Department of Physics, University of Wisconsin, Madison, WI, 53706, USA
| | - Alexandra Tits
- Mechanics of Biological and Bioinspired Materials Laboratory, Department of Aerospace and Mechanical Engineering, University of Liège, Liège, B-4000, Belgium
| | - Connor A Schmidt
- Department of Physics, University of Wisconsin, Madison, WI, 53706, USA
- Department of Chemistry, University of Wisconsin, Madison, WI, 53706, USA
| | - Andreas Scholl
- Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA
| | - Astrid Cantamessa
- Mechanics of Biological and Bioinspired Materials Laboratory, Department of Aerospace and Mechanical Engineering, University of Liège, Liège, B-4000, Belgium
| | - Laura Müller
- Mechanics of Biological and Bioinspired Materials Laboratory, Department of Aerospace and Mechanical Engineering, University of Liège, Liège, B-4000, Belgium
| | - Yann Delaunois
- Laboratory of Functional and Evolutionary Morphology (FOCUS Research Unit) and Center for Applied Research and Education in Microscopy (CAREM), University of Liège, Liège, B-4000, Belgium
| | - Philippe Compère
- Laboratory of Functional and Evolutionary Morphology (FOCUS Research Unit) and Center for Applied Research and Education in Microscopy (CAREM), University of Liège, Liège, B-4000, Belgium
| | - Davide Ruffoni
- Mechanics of Biological and Bioinspired Materials Laboratory, Department of Aerospace and Mechanical Engineering, University of Liège, Liège, B-4000, Belgium
| | - Markus J Buehler
- Laboratory for Atomistic and Molecular Mechanics (LAMM), Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, MA, 02139, USA
| | - Pupa U P A Gilbert
- Department of Physics, University of Wisconsin, Madison, WI, 53706, USA
- Department of Chemistry, University of Wisconsin, Madison, WI, 53706, USA
- Departments of Materials Science and Engineering, Geoscience, University of Wisconsin, Madison, WI, 53706, USA
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA
| |
Collapse
|
10
|
Müller L, Schneider A, Kühl M, Kühl SJ. [The Climate Change Challenge: How to get research into society through an online workshop]. Z Evid Fortbild Qual Gesundhwes 2023; 176:82-89. [PMID: 36702640 DOI: 10.1016/j.zefq.2022.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 10/13/2022] [Accepted: 10/25/2022] [Indexed: 01/26/2023]
Abstract
BACKGROUND According to the World Health Organisation, climate change poses the greatest health threat to humanity. At the same time, an environmentally friendly lifestyle has a positive impact on our health, such as a plant-based diet. In order to counter climate change, society needs to be informed about climate-friendly and health-promoting measures. Therefore, an online workshop was initiated at the Medical Faculty of Ulm. In an accompanying study, it was determined whether this leads to changes in environmental knowledge and awareness among the participants. METHODS The online workshop consisted of four 2-hour sessions. Scientific basics on climate change and possible solutions were discussed. Other focuses were on health and the health system as well as environmental psychology and climate change denial. Participants could take part in an anonymous and voluntary online survey before (pretest) and after (posttest) the workshop. RESULTS 86 participants took part in the workshop, of whom 24 attended all appointments and completed both surveys. While hardly any changes were observed in the subsection of environmental emotion, perception and behavior, there was a significant increase in environmental knowledge in the posttest. The workshop was evaluated very positively. Furthermore, many participants were motivated to make a personal contribution to climate protection after the workshop. CONCLUSION The workshop serves as a good example of how medical scientific findings can be shared at a societal level. The participants already showed a high level of environmental awareness in the pretest, which is why the question remains open as to how people can be sensitized to the (health) threats posed by climate change who do not proactively sign up for such an offer themselves.
Collapse
Affiliation(s)
- Laura Müller
- Institut für Biochemie und Molekulare Biologie, Medizinische Fakultät, Universität Ulm, Ulm, Deutschland
| | - Achim Schneider
- Studiendekanat, Bereich Lehrforschung, Medizinische Fakultät, Universität Ulm, Ulm, Deutschland
| | - Michael Kühl
- Institut für Biochemie und Molekulare Biologie, Medizinische Fakultät, Universität Ulm, Ulm, Deutschland
| | - Susanne J Kühl
- Institut für Biochemie und Molekulare Biologie, Medizinische Fakultät, Universität Ulm, Ulm, Deutschland.
| |
Collapse
|
11
|
Petko D, Cantieni A, Schmid R, Müller L, Krannich M, Michos K. Technology acceptance of a mobile portfolio app for teacher education: Pre-service teachers views on multimedia-based note-taking and mentoring in internships. J Digit Learn Teach Educ 2023; 39:57-71. [PMID: 36935904 PMCID: PMC10015597 DOI: 10.1080/21532974.2022.2142990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Mobile technologies are promising tools to scaffold teaching practice. In this study, we developed and tested a mobile app for teacher education. This mobile portfolio enables multimedia-based note-taking, reflection, and discussion with peers and mentors. We conducted two studies to explore the effect of design variants and use scenarios on the app's acceptance. In the first study with N = 83 pre-service primary school teachers, technology acceptance was higher for those using the app with multimedia note-taking functionality than for those using the same app with this functionality disabled. In the second study with N = 81 pre-service teachers, those using the app together with their mentor teachers reported levels of technology acceptance similar to those who used the app exclusively among themselves. In consequence, a mobile portfolio app would be met with higher acceptance if it builds reflection upon multimedia note-taking both with and without the inclusion of mentors.
Collapse
Affiliation(s)
- Dominik Petko
- Institute of Education, University of Zurich, Zurich, Switzerland
- CONTACT Dominik Petko Institute of Education, University of Zurich, Kantonsschulstrasse 3, Zurich, CH-8001, Switzerland
| | - Andrea Cantieni
- Institute of Education, University of Zurich, Zurich, Switzerland
| | | | - Laura Müller
- Schwyz University of Teacher Education, Switzerland
| | - Maike Krannich
- Institute of Education, University of Zurich, Zurich, Switzerland
| | | |
Collapse
|
12
|
Müller L, Rosenbaum C, Krause J, Weitschies W. Characterization of an In Vitro/Ex Vivo Mucoadhesiveness Measurement Method of PVA Films. Polymers (Basel) 2022; 14:polym14235146. [PMID: 36501540 PMCID: PMC9741245 DOI: 10.3390/polym14235146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 11/23/2022] [Accepted: 11/24/2022] [Indexed: 11/30/2022] Open
Abstract
Transmucosal drug delivery systems can be an attractive alternative to conventional oral dosage forms such as tablets. There are numerous in vitro methods to estimate the behavior of mucoadhesive dosage forms in vivo. In this work, a tensile test system was used to measure the mucoadhesion of polyvinyl alcohol films. An in vitro screening of potential influencing variables was performed on biomimetic agar/mucin gels. Among the test device-specific factors, contact time and withdrawal speed were identified as influencing parameters. In addition, influencing factors such as the sample area, which showed a linear relationship in relation to the resulting work, and the liquid addition, which led to an abrupt decrease in adhesion, could be identified. The influence of tissue preparation was investigated in ex vivo experiments on porcine small intestinal tissue. It was found that lower values of Fmax and Wad were obtained on processed and fresh tissue than on processed and thawed tissue. Film adhesion on fresh, unprocessed tissue was lowest in most of the animals tested. Comparison of ex vivo measurements on porcine small intestinal tissue with in vitro measurements on agar/mucin gels illustrates the inter- and intra-individual variability of biological tissue.
Collapse
|
13
|
Schmidt M, Lübbe K, Decker T, Thill M, Bauer L, Müller V, Link T, Furlanetto J, Reinisch M, Mundhenke C, Hoffmann O, Zahn MO, Müller L, Denkert C, van Mackelenbergh M, Fasching P, Burchardi N, Nekljudova V, Loibl S. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE). ESMO Open 2022; 7:100601. [PMID: 36356410 PMCID: PMC9832733 DOI: 10.1016/j.esmoop.2022.100601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Revised: 09/14/2022] [Accepted: 09/15/2022] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Stomatitis is one of the main reasons to discontinue everolimus in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). To decrease stomatitis and subsequently early treatment discontinuations or dose reductions, the DESIREE trial investigated the use of a stepwise dose-escalation schedule of everolimus (EVE esc). PATIENTS AND METHODS DESIREE is a phase II, multicentre, randomised, double-blind, placebo-controlled trial in patients with HR+/HER2- mBC and progression/relapse after nonsteroidal aromatase inhibitor treatment. Patients were randomised to EVE esc (2.5 mg/day, week 1; 5 mg/day, week 2; 7.5 mg/day, week 3; 10 mg/day, weeks 4-24) or everolimus 10 mg/day (EVE 10mg) for 24 weeks plus exemestane. The primary endpoint was the incidence of stomatitis episodes grade ≥2 within 12 weeks of treatment. The secondary endpoints included toxicity, relative total dose intensity (RTDI) and quality of life (QoL). RESULTS A total of 160 patients were randomised and 156 started treatment (EVE esc: 80; EVE 10mg: 76). The median age of patients was 64 years (range 33-85), 56.3% patients in the EVE esc arm versus 42.1% in the EVE 10mg arm had liver metastasis (P = 0.081) and 62.5% versus 51.3% received over one metastatic therapy line (P = 0.196). Within 12 weeks, the incidence of stomatitis episodes grade ≥2 was significantly lower in the EVE esc arm compared with the EVE 10mg arm (28.8% versus 46.1%; odds ratio 0.47, 95% confidence interval 0.24-0.92; P = 0.026). Toxicity was in line with the known safety profile without new safety concerns. The median RTDI was 91.1% in the EVE esc arm versus 80.0% in the EVE 10mg arm (P = 0.329). Discontinuation rate in the first 3 weeks was 6.3% versus 15.8%, respectively (P = 0.073). QoL was comparable between the two treatment arms. CONCLUSIONS A dose-escalation schema of everolimus over 3 weeks can be successfully used to reduce the incidence of high-grade stomatitis in the first 12 weeks of treatment in patients with HR+/HER2- mBC. TRIAL REGISTRATION ClinicalTrials.govNCT02387099; https://clinicaltrials.gov/ct2/show/NCT02387099.
Collapse
Affiliation(s)
- M. Schmidt
- Universitätsmedizin Mainz, Mainz, Germany
| | - K. Lübbe
- Diakovere Henriettenstift Hannover, Hanover, Germany
| | - T. Decker
- Onkologie und Hämatologie Ravensburg, Ravensburg, Germany
| | - M. Thill
- Klinik für Gynäkologie und Gynäkologische Onkologie, Agaplesion Markus Krankenhaus, Frankfurt, Germany
| | - L. Bauer
- GRN gGmbH Klinik Weinheim, Weinheim, Germany
| | - V. Müller
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - T. Link
- Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany
| | | | - M. Reinisch
- Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany
| | - C. Mundhenke
- Brustzentrum, Gynäkologisches Krebszentrum, Perinatalzentrum Level I, Klinikum Bayreuth, Bayreuth, Germany
| | | | - M.-O. Zahn
- MVZ Onkologische Kooperation Harz Dres./Zahn Fachärzte für Innere Medizin, Goslar, Germany
| | | | - C. Denkert
- Institut für Pathologie, Philipps-Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, Germany
| | - M. van Mackelenbergh
- Universitätsklinikum Schleswig-Holstein, Klinik für Gynäkologie und Geburtshilfe, Schleswig-Holstein, Kiel, Germany
| | | | | | | | - S. Loibl
- German Breast Group, Neu-Isenburg, Germany,Correspondence to: Prof. Sibylle Loibl, German Breast Group, Dornhofstr. 10, 63263 Neu-Isenburg, Germany. Tel: +49 6102 7480 335 @GBG_Forschunghttps://twitter.com/GBG_Forschung
| |
Collapse
|
14
|
Graafen D, Müller L, Halfmann M, Düber C, Hahn F, Yang Y, Emrich T, Kloeckner R. Photon-counting detector CT improves quality of arterial phase abdominal scans: A head-to-head comparison with energy-integrating CT. Eur J Radiol 2022; 156:110514. [PMID: 36108479 DOI: 10.1016/j.ejrad.2022.110514] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Revised: 08/26/2022] [Accepted: 09/03/2022] [Indexed: 11/19/2022]
Abstract
PURPOSE Photon-counting detector (PCD)-CT is expected to have a substantial impact on oncologic abdominal imaging. We compared subjective and objective image quality between PCD-CT and conventional energy-integrating detector (EID-)CT arterial phase abdominal scans. METHODS This study included 84 patients undergoing both types of abdominal CT. EID-CT scans were acquired with a tube voltage of 100 kVp. With PCD-CT, acquired with 120-kVp, we reconstructed polychromatic T3D images and virtual monoenergetic images (VMIs) in 10-keV intervals from 40 to 90 keV. Quantitative image analysis included noise and contrast-to-noise ratio (CNR) of hepatic vessels, kidney cortex, and hypervascular liver lesions to liver parenchyma. Three raters used a 5-point Likert scale for qualitative image analysis of image noise and contrast, lesion conspicuity, and overall image quality. Radiation dose exposure (CT dose index) was compared between the two CT types. RESULTS Mean CT dose index and effective dose were respectively 18 % and 26 % lower with PCD-CT versus EID-CT. Compared with EID-CT, CNRs of kidney cortex and vessel to liver parenchyma were significantly higher in PCD-CT VMIs at energies ≤ 60 keV and in polychromatic T3D images (p < 0.004). Overall image quality of PCD-CT VMIs at 50 and 60 keV was rated as significantly better (p < 0.01) than the EID-CT images (inter-reader agreement alpha = 0.80). Lesion conspicuity was significantly better in low-keV VMIs (p < 0.03) and worse in > 70-keV VMIs. CONCLUSIONS With low-keV VMI, PCD-CT yields significantly improved objective and subjective quality of arterial phase oncological imaging compared with EID-CT. This advantage may translate into higher diagnostic confidence and lower radiation dose protocols.
Collapse
Affiliation(s)
- D Graafen
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
| | - L Müller
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
| | - M Halfmann
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; German Center for Cardiovascular Research (DZHK), Partner-Site Rhine-Main, Mainz, Germany
| | - C Düber
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
| | - F Hahn
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
| | - Y Yang
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
| | - T Emrich
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; German Center for Cardiovascular Research (DZHK), Partner-Site Rhine-Main, Mainz, Germany
| | - R Kloeckner
- Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
| |
Collapse
|
15
|
Noseda R, Müller L, Stammschulte T, Bertoli R, Ceschi A. Spikevax booster and delayed urticaria: a Swiss signal with diagnostic uncertainties due to a high proportion of direct patient reports. Eur J Clin Pharmacol 2022; 78:2021-2022. [PMID: 36255481 PMCID: PMC9579652 DOI: 10.1007/s00228-022-03404-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Accepted: 10/11/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Roberta Noseda
- Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Via Tesserete 46, 6900, Lugano, Switzerland
| | - Laura Müller
- Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Via Tesserete 46, 6900, Lugano, Switzerland
| | | | - Raffaela Bertoli
- Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Via Tesserete 46, 6900, Lugano, Switzerland
| | - Alessandro Ceschi
- Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Via Tesserete 46, 6900, Lugano, Switzerland.
| |
Collapse
|
16
|
Welt A, Zahn MO, Wöckel A, Stickeler E, Thoma M, Nusch A, Fuxius S, Müller L, Reschke D, Chiabudini M, Hillebrand L, Kruggel L, Jänicke M, Marschner N, Thill M, Harbeck N, Decker T. 187P Routine care of early breast cancer (stage I-III) in Germany: Data of the prospective, intersectoral research platform OPAL. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
17
|
Stöhr F, Klöckner R, Mähringer-Kunz A, Düber C, Müller L, Schnier M, Hahn F. Vorhersage von makrovaskulärer Infiltration beim HCC – eine Radiomics-Studie. ROFO-FORTSCHR RONTG 2022. [DOI: 10.1055/s-0042-1749933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- F Stöhr
- Universitätsmedizin Mainz, Klinik und Poliklinik für diagnostische und Interventionelle, Mainz
| | - R Klöckner
- Klinik für diagnostische und interventionelle Radiologie, Universitätsmedizin Mainz, Mainz
| | - A Mähringer-Kunz
- Klinik für diagnostische und interventionelle Radiologie, Universitätsmedizin Mainz, Mainz
| | - C Düber
- Klinik für diagnostische und interventionelle Radiologie, Universitätsmedizin Mainz, Mainz
| | - L Müller
- Klinik für diagnostische und interventionelle Radiologie, Universitätsmedizin Mainz, Mainz
| | - M Schnier
- Klinik für diagnostische und interventionelle Radiologie, Universitätsmedizin Mainz, Mainz
| | - F Hahn
- Klinik für diagnostische und interventionelle Radiologie, Universitätsmedizin Mainz, Mainz
| |
Collapse
|
18
|
Sommerhäuser G, Kurreck A, Stintzing S, Heinemann V, von Weikersthal LF, Dechow T, Kaiser F, Karthaus M, Schwaner I, Fuchs M, König A, Roderburg C, Hoyer I, Quante M, Kiani A, Fruehauf S, Müller L, Reinacher-Schick A, Ettrich TJ, Stahler A, Modest DP. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer. BMC Cancer 2022; 22:820. [PMID: 35897060 PMCID: PMC9327141 DOI: 10.1186/s12885-022-09892-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 07/13/2022] [Indexed: 01/05/2023] Open
Abstract
Background Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is usually based on two- or three-drug chemotherapy regimens with fluoropyrimidine (5-fluorouracil (5-FU) or capecitabine), oxaliplatin and/or irinotecan, combined with either anti-VEGF (bevacizumab) or, for RAS wild-type (WT) tumors, anti-EGFR antibodies (panitumumab or cetuximab). Recommendations for patients who are not eligible for intensive combination therapies are limited and include fluoropyrimidine plus bevacizumab or single agent anti-EGFR antibody treatment. The use of a monochemotherapy concept of trifluridine/ tipiracil in combination with monoclonal antibodies is not approved for first-line therapy, yet. Results from the phase II TASCO trial evaluating trifluridine/ tipiracil plus bevacicumab in first-line treatment of mCRC patients and from the phase I/II APOLLON trial investigating trifluridine/ tipiracil plus panitumumab in pre-treated mCRC patients suggest favourable activity and tolerability of these new therapeutic approaches. Methods FIRE-8 (NCT05007132) is a prospective, randomized, open-label, multicenter phase II study which aims to evaluate the efficacy of first-line treatment with trifluridine/tipiracil (35 mg/m2 body surface area (BSA), orally twice daily on days 1–5 and 8–12, q28 days) plus either the anti-EGFR antibody panitumumab (6 mg/kg body weight, intravenously on day 1 and 15, q28 days) [arm A] or (as control arm) the anti-VEGF antibody bevacizumab (5 mg/kg body weight, intravenously on day 1 and 15, q28 days) [arm B] in RAS WT mCRC patients. The primary objective is to demonstrate an improved objective response rate (ORR) according to RECIST 1.1 from 30% (control arm) to 55% with panitumumab. With a power of 80% and a two-sided significance level of 0.05, 138 evaluable patients are needed. Given an estimated drop-out rate of 10%, 153 patients will be enrolled. Discussion To the best of our knowledge, this is the first phase II trial to evaluate the efficacy of trifluridine/tipiracil plus panitumumab in first-line treatment of RAS WT mCRC patients. The administration of anti-EGFR antibodies rather than anti-VEGF antibodies in combination with trifluridine/tipiracil may result in an increased initial efficacy. Trial registration EU Clinical Trials Register (EudraCT) 2019-004223-20. Registered October 22, 2019, ClinicalTrials.govNCT05007132. Registered on August 12, 2021. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-022-09892-8.
Collapse
Affiliation(s)
- G Sommerhäuser
- Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - A Kurreck
- Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - S Stintzing
- Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.,German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany
| | - V Heinemann
- German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany.,Department of Hematology/Oncology, LMU Klinikum, University of Munich, Comprehensive Cancer Center Munich, Munich, Germany
| | | | - T Dechow
- Oncological Practice, Ravensburg, Germany
| | - F Kaiser
- Oncological Practice, Landshut, Germany
| | - M Karthaus
- Department of Hematology and Oncology, Klinikum Neuperlach/ Klinikum Harlaching, Munich, Germany
| | - I Schwaner
- Oncological Practice Kurfuerstendamm, Berlin, Germany
| | - M Fuchs
- Department of Gastroenterology, Hepatology, and Gastrointestinal Oncology, München Klinik Bogenhausen, Munich, Germany
| | - A König
- Department of Gastroenterology and Gastrointestinal Oncology Goettingen, University Medical Center Goettingen, Goettingen, Germany
| | - C Roderburg
- Department of Gastroenterology, Hepatology, and Infectiology, University Medical Center Duesseldorf, Duesseldorf, Germany
| | - I Hoyer
- Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - M Quante
- Department of Gastroenterology, Hepatology, Endocrinology, and Infectiology, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany
| | - A Kiani
- Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, Germany
| | - S Fruehauf
- Department of Hematology, Oncology, and Palliative Care, Klinik Dr. Hancken GmbH, Stade, Germany
| | - L Müller
- Onkologie UnterEms, Leer, Germany
| | - A Reinacher-Schick
- Department of Hematology, Oncology and Palliative Care, Ruhr-University Bochum, Bochum, Germany
| | - T J Ettrich
- Department of Internal Medicine, University Hospital Ulm, Ulm, Germany
| | - A Stahler
- Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - D P Modest
- Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. .,German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany.
| |
Collapse
|
19
|
Kugler M, Dellinger M, Kartnig F, Tosevska A, Müller L, Preglej T, Heinz L, Kiener H, Steiner G, Aletaha D, Karonitsch TM, Bonelli M. OP0079 SYNOVIAL FIBROBLASTS – T CELL INTERACTIONS ARE MAJOR DRIVERS OF INFLAMMATION: A CLOSER LOOK INTO THE JOINT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundRheumatoid Arthritis (RA) is a chronic inflammatory disease, which is characterized by synovial inflammation resulting in bone and cartilage destruction. Crosstalk between activated fibroblast-like synoviocytes (FLS) and immune cells, such as CD4+ T cells, within the synovium might amplify synovial inflammation and joint destruction.ObjectivesTo define the interaction profile of activated FLS and CD4+ T cells within an inflammatory setting and to elucidate its consequence on synovial inflammation.MethodsTo screen for factors that activate FLS in RA, isolated FLS were treated with different inflammatory cytokines and transcriptomic changes were measured with RNA-seq. Fluorescence activated cell sorting (FACS) purified naïve CD4+ T-cells from the same patients were co-cultured with the cytokine pre-treated FLS. Automated fluorescence microscopy and downstream bioinformatic image analysis allowed visualization and quantification of cell-cell interactions. After co-culture T-cells were isolated and T-cell activation, proliferation and differentiation was determined by flow cytometry.ResultsTo model the in vivo situation, FLS were pre-stimulated with different pro- and anti-inflammatory cytokines. RNA-seq revealed cytokine specific activation patterns of FLS. Correspondingly, we observed distinct CD4+ T cells – FLS interaction profiles depending on the cytokine used for FLS activation. In line with distinct interaction profiles, specific patterns in CD4+ T cells activation, proliferation and differentiation of naïve T cells into CD62Lhigh CD45ROhigh memory T cells could be detected. Signatures of cytokine-stimulated FLS could be identified in transcriptomic data from synovial tissue samples.ConclusionWithin this study, we describe how cytokine induced CD4+ T cells – FLS interactions impact on T-cell proliferation, activation and differentiation.References[1]Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019.[2]Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.[3]Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet. 2016;388(10055):2023-38.[4]Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233-55.[5]Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019.Disclosure of InterestsNone declared.
Collapse
|
20
|
Müller L, Mitter S, Mannewitz M, Keilmann L, Meister S, Kolben MT, Schmoeckel E, Burges A, Trillsch F, Czogalla B, Jeschke U, Kessler M, Mahner S, Kolben T, Beyer S. Die Blutgruppenantigene SLeX, SLeA and Lewis Y als potenziell prognostische Faktoren im Endometrium- und Zervixkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Affiliation(s)
- L Müller
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mitter
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Mannewitz
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Keilmann
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Meister
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Schmoeckel
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - A Burges
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - B Czogalla
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - M Kessler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
21
|
Mitter S, Müller L, Mannewitz M, Keilmann L, Meister S, Kolben MT, Schmoeckel E, Burges A, Trillsch F, Czogalla B, Mahner S, Kessler M, Jeschke U, Kolben T, Beyer S. RIG-I – Expression als negativer prognostischer Faktor im Endometriumkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- S Mitter
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Müller
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Mannewitz
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Keilmann
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Meister
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Schmoeckel
- Pathologisches Institut, Universitätsklinikum der LMU, München
| | - A Burges
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - B Czogalla
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Kessler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
22
|
Spies CK, Unglaub F, Bruckner T, Müller L, Eysel P, Rau J. Diagnostic accuracy of wrist MRI in comparison to wrist arthroscopy regarding TFCC lesions in clinical practice. Arch Orthop Trauma Surg 2022; 142:879-885. [PMID: 35006371 DOI: 10.1007/s00402-021-04329-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Accepted: 12/19/2021] [Indexed: 11/26/2022]
Abstract
INTRODUCTION The purpose of this study was to arthroscopically verify MRI diagnostic accuracy for triangular fibrocartilage complex (TFCC) lesions in a regular clinical environment. METHODS A total of 859 patients' data with both preoperative MRI of the wrist and additional wrist arthroscopy were retrospectively reviewed. Two board-certified hand surgeons and one orthopaedic surgeon executed wrist arthroscopy, whereas more than 100 radiologists examined the MRI of the wrist. The accordance of TFCC lesion classification using MRI in comparison to wrist arthroscopy and diagnostic precision of the former depending on technical details were evaluated. RESULTS Diagnostic accuracy of MRI for TFCC lesions is poor in comparison to wrist arthroscopy as the reference standard. Technical specifications for MRI of the wrist are heterogeneous among the radiologists. These parameters have not improved accuracy of TFCC evaluation at large. CONCLUSION The accuracy of MRI in a regular clinical environment still remains inferior to wrist arthroscopy for detection of TFCC lesions. Development of a standard MRI protocol may be implemented on a regular basis and application of the Palmer classification for TFCC lesion should be sought.
Collapse
Affiliation(s)
- C K Spies
- Hand Surgery, Spital Langenthal, Spital Region Oberaargau SRO AG, 4900, Langenthal, Switzerland.
| | - F Unglaub
- Hand Surgery, Vulpius Klinik, Vulpiusstraße 29, 74906, Bad Rappenau, Germany
- Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - T Bruckner
- Department of Medical Biometry and Informatics, University Heidelberg, Im Neuenheimer Feld 305, 69120, Heidelberg, Germany
| | - L Müller
- Department of Orthopaedic Surgery and Traumatology, University Hospital Cologne, Kerpener Str. 62, 50937, Köln, Germany
| | - P Eysel
- Department of Orthopaedic Surgery and Traumatology, University Hospital Cologne, Joseph-Stelzmann-Str. 24, 50931, Köln, Germany
| | - J Rau
- Hand Surgery, Vulpius Klinik, Vulpiusstraße 29, 74906, Bad Rappenau, Germany
- Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| |
Collapse
|
23
|
Stock S, Al Wheibi S, Topal A, Gross TS, Müller L, Owais T, Kloth B, Girdauskas E. Implementation of Standardized ERAS Protocol in Patients Undergoing Minimally Invasive Heart Surgery. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- S. Stock
- Department of Cardiac and Thoracic Surgery, University Hospital Augsburg, Augsburg, Deutschland
| | - S. Al Wheibi
- Department of Cardiac and Thoracic Surgery, University Hospital Augsburg, Augsburg, Deutschland
| | - A. Topal
- Department of Cardiac and Thoracic Surgery, University Hospital Augsburg, Augsburg, Deutschland
| | - T.M. Sequeira Gross
- Department of Cardiac and Thoracic Surgery, University Hospital Augsburg, Augsburg, Deutschland
| | - L. Müller
- Department of Cardiac and Thoracic Surgery, University Hospital Augsburg, Augsburg, Deutschland
| | - T. Owais
- Department of Cardiac and Thoracic Surgery, University Hospital Augsburg, Augsburg, Deutschland
| | - B. Kloth
- Department of Cardiac and Thoracic Surgery, University Hospital Augsburg, Augsburg, Deutschland
| | - E. Girdauskas
- Department of Cardiac and Thoracic Surgery, University Hospital Augsburg, Augsburg, Deutschland
| |
Collapse
|
24
|
Holfeld J, Gollmann-Tepeköylü C, Graber M, Nägele F, Oezpeker CU, Stastny L, Hoefer D, Müller L, Grimm M, Bonaros N. The Impact of Era and Technical Innovation on Outcome and Operative Times in Minimally Invasive Mitral Surgery. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
| | | | | | | | | | - L. Stastny
- University of Innsbruck, Innsbruck, Austria
| | | | | | | | | |
Collapse
|
25
|
Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021; 6:100299. [PMID: 34839105 PMCID: PMC8637493 DOI: 10.1016/j.esmoop.2021.100299] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 09/25/2021] [Accepted: 10/11/2021] [Indexed: 10/31/2022] Open
Abstract
BACKGROUND Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors. PATIENTS AND METHODS Patients with HER2-negative MBC were screened for participation in DETECT III and IV trials before the initiation of a new line of therapy. Blood samples were analyzed using CELLSEARCH. CTCs were labeled with an anti-HER2 antibody and classified according to staining intensity (negative, weak, moderate, or strong staining). RESULTS Screening blood samples were analyzed in 1933 patients with HER2-negative MBC. As many as 1217 out of the 1933 screened patients (63.0%) had ≥1 CTC per 7.5 ml blood; ≥5 CTCs were detected in 735 patients (38.0%; range 1-35 078 CTCs, median 8 CTCs). HER2 status of CTCs was assessed in 1159 CTC-positive patients; ≥1 CTC with strong HER2 staining was found in 174 (15.0%) patients. The proportion of CTCs with strong HER2 staining among all CTCs of an individual patient ranged between 0.06% and 100% (mean 15.8%). Patients with estrogen receptor (ER)- and progesterone receptor (PR)-positive tumors were more likely to harbor ≥1 CTC with strong HER2 staining. CTC status was significantly associated with overall survival (OS). Detection of ≥1 CTC with strong HER2 staining was associated with shorter OS [9.7 (7.1-12.3) versus 16.5 (14.9-18.1) months in patients with CTCs with negative-to-moderate HER2 staining only, P = 0.013]. In multivariate analysis, age, ER status, PR status, Eastern Cooperative Oncology Group performance status, therapy line, and CTC status independently predicted OS. CONCLUSION CTC detection in patients with HER2-negative disease is a strong prognostic factor. Presence of ≥1 CTC with strong HER2 staining was associated with shorter OS, supporting a biological role of HER2 expression on CTCs.
Collapse
Affiliation(s)
- V Müller
- Department of Gynecology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
| | - M Banys-Paluchowski
- Gynecology and Obstetrics Department, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Medical Faculty, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany
| | - T W P Friedl
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - P A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - A Schneeweiss
- Division Gynecologic Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
| | - A Hartkopf
- Department of Gynecology and Obstetrics, University Hospital Tübingen, Tübingen, Germany
| | - D Wallwiener
- Department of Gynecology and Obstetrics, University Hospital Tübingen, Tübingen, Germany
| | - B Rack
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - F Meier-Stiegen
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
| | - J Huober
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - M Rübner
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - O Hoffmann
- Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
| | - L Müller
- OnkologieUnterEms, Leer, Germany
| | - W Janni
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - P Wimberger
- Department of Gynecology and Obstetrics, University Hospital Carl Gustav Carus Dresden, TU Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germany
| | - B Jäger
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
| | - K Pantel
- Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - S Riethdorf
- Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - N Harbeck
- Breast Center, Department of Gynecology and Obstetrics and CCC Munich, LMU University Hospital, Munich, Germany
| | - T Fehm
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
| |
Collapse
|
26
|
Peifer R, Müller L, Hoof S, Beckmann F, Cula B, Limberg C. Mimicking of the histidine brace structural motif in molecular copper(I) compounds. Z Anorg Allg Chem 2021. [DOI: 10.1002/zaac.202100145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. Peifer
- Institut für Chemie Humboldt-Universität zu Berlin Brook-Taylor-Straße 2 12489 Berlin Germany
| | - L. Müller
- Institut für Chemie Humboldt-Universität zu Berlin Brook-Taylor-Straße 2 12489 Berlin Germany
| | - S. Hoof
- Institut für Chemie Humboldt-Universität zu Berlin Brook-Taylor-Straße 2 12489 Berlin Germany
| | - F. Beckmann
- Institut für Chemie Humboldt-Universität zu Berlin Brook-Taylor-Straße 2 12489 Berlin Germany
| | - B. Cula
- Institut für Chemie Humboldt-Universität zu Berlin Brook-Taylor-Straße 2 12489 Berlin Germany
| | - C. Limberg
- Institut für Chemie Humboldt-Universität zu Berlin Brook-Taylor-Straße 2 12489 Berlin Germany
| |
Collapse
|
27
|
Mair M, Tomasich E, Heller G, Müller L, Wöhrer A, Kiesel B, Widhalm G, Dieckmann K, Hainfellner J, Preusser M, Berghoff A. 343MO Clinical features and DNA methylation patterns in long- and short-term survivors of WHO grade II-III glioma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
28
|
Vogel A, Behringer D, Bröckling S, Chater J, Derigs HG, Fietz T, Götze T, Hartmann F, Lutz M, Müller L, Moosmann N, Moulin JC, Potenberg J, Saborowski A, Späth-Schwalbe E, Schuler M, Pauligk C, Westphalen C, Zäpf B, Al-Batran SE. 1871TiP PLATON – “Platform for Analyzing Targetable Tumor Mutations”: A pilot study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.758] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
29
|
Loibl S, Schmidt M, Lübbe K, Decker T, Thill M, Bauer L, Müller V, Link T, Furlanetto J, Kümmel S, Mundhenke C, Hoffmann O, Zahn MO, Müller L, Denkert C, van Mackelenbergh M, Fasching P, Burchardi N, Nekljudova V. LBA19 A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
30
|
Weitschies W, Müller L, Grimm M, Koziolek M. Ingestible devices for studying the gastrointestinal physiology and their application in oral biopharmaceutics. Adv Drug Deliv Rev 2021; 176:113853. [PMID: 34192551 DOI: 10.1016/j.addr.2021.113853] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 06/22/2021] [Accepted: 06/23/2021] [Indexed: 12/17/2022]
Abstract
Ingestible sensor systems are unique tools for obtaining physiological data from an undisturbed gastrointestinal tract. Since their dimensions correspond to monolithic oral dosage forms, such as enteric coated tablets or hydrogel matrix tablets, they also allow insights into the physiological conditions experienced by non-disintegrating dosage forms on their way through the gastrointestinal tract. In this work, the different ingestible sensor systems which can be used for this purpose are described and their potential applications as well as difficulties and pitfalls with respect to their use are presented. It is also highlighted how the data on transit times, pH, temperature and pressure as well as the data from different animal models commonly used in drug product development such as dogs and pigs have contributed to a deeper mechanistic understanding of oral drug delivery.
Collapse
Affiliation(s)
- Werner Weitschies
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany.
| | - Laura Müller
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Michael Grimm
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Mirko Koziolek
- NCE Formulation Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
| |
Collapse
|
31
|
Darr C, Zschäbitz S, Ivanyi P, Wirth M, Staib P, Schostak M, Müller L, Metz M, Bergmann L, Steiner T, Lorch A, Schütt P, Rafiyan MR, Hellmis E, Hinke A, Mänz M, Meiler J, Kretz T, Flörcken A, Grünwald V. 679P Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Smola A, Samadzadeh S, Müller L, Adams O, Homey B, Albrecht P, Meller S. Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol 2021; 35:e743-e745. [PMID: 34310766 PMCID: PMC8447380 DOI: 10.1111/jdv.17549] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 07/01/2021] [Accepted: 07/21/2021] [Indexed: 01/12/2023]
Affiliation(s)
- A Smola
- Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
| | - S Samadzadeh
- Department of Neurology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
| | - L Müller
- Institute of Virology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
| | - O Adams
- Institute of Virology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
| | - B Homey
- Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
| | - P Albrecht
- Department of Neurology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
| | - S Meller
- Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
| |
Collapse
|
33
|
Müller L, Alm J. Feasibility and Potential Significance of Prophylactic Ablation of the Major Ascending Tributaries in Endovenous Laser Ablation (EVLA) of the Great Saphenous Vein: A Case Series. J Vasc Surg Venous Lymphat Disord 2021. [DOI: 10.1016/j.jvsv.2021.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Müller L, De Rooy D. Digital biomarkers for the prediction of mental health in aviation personnel. BMJ Health Care Inform 2021; 28:bmjhci-2021-100335. [PMID: 33980501 PMCID: PMC8118040 DOI: 10.1136/bmjhci-2021-100335] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 04/26/2021] [Indexed: 11/30/2022] Open
Affiliation(s)
- Laura Müller
- Psychiatry, Leiden University Medical Center, Leiden, The Netherlands
| | - Diederik De Rooy
- Psychiatry, Leiden University Medical Center, Leiden, The Netherlands .,Transparant Mental Healthcare, Leiden, The Netherlands
| |
Collapse
|
35
|
Müller L, El Oakley R, Saad M, Mokdad AH, Etolhi GA, Flahault A. A multidimensional framework for rating health system performance and sustainability: A nine plus one ranking system. J Glob Health 2021; 11:04025. [PMID: 34026052 PMCID: PMC8109277 DOI: 10.7189/jogh.11.04025] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Background Health Care provision in terms of prevention, detection and treatment is primarily dependent on the quality of the hosting Health System. In its health report 2000, the WHO's attempt to assess and rank health systems’ quality Worldwide was heavily criticized. We propose a novel framework for health system performance and ranking using three indicators for three domains; general health system performance, clinical outcome of treatment applied to the main causes of death and health system sustainability domains. Methods Each domain was rated as “A – high”, “B – intermediate” or “C – poor” according to the aggregate score values of its three indicators. Hence the highest rank a health system can achieve is “AAA” and the lowest is “CCC”. If there is a need to define a “numerical rank” to further differentiate health systems with similar rating from one another, the total health expenditure per capita per year was used as an additional “number 10” indicator to achieve that level of differentiation. The framework was applied to Health Systems serving most of the World population including China, India, Brazil, USA, Russia, Germany, Japan, UK, France, Singapore and Switzerland. Data pertinent to each indicator was captured from published reports in peer-reviewed journals and/or from official websites. A Delphi survey was conducted for data not available online. Results Among the 11 health systems tested, no one scored AAA, Switzerland, France, Germany and Japan scored AAB, Singapore scored ABB, UK scored BBB, USA, Russia and China scored BBC, Brazil scored BCC while India scored CCC. Total health expenditure per capita per year lead to ranking Switzerland first followed by France, Germany, and Japan. Conclusion This novel ranking system is a practical and an applicable tool that test health system performance and sustainability. It can be utilized to guide all organizations, people and actions whose primary intent is to promote, restore or maintain health to achieve their targets. An International Health System Ranking database that will be hosted by the Institute of Global, Health, Faculty of Medicine, University of Geneva, Switzerland.
Collapse
Affiliation(s)
- Laura Müller
- Institute of Global, Health, Faculty of Medicine, University of Geneva, Switzerland
| | - Reida El Oakley
- Cardiac Centre, King Abdel Aziz Specialist Hospital, Taif, Saudi Arabia
| | - Mohammed Saad
- The Libyan International Medical University, Benghazi, Libya
| | - Ali H Mokdad
- Institute for Health Metrics and Evaluation, University of Washington, Seattle,Washington, USA
| | - Giamal A Etolhi
- The Libyan International Medical University, Benghazi, Libya
| | - Antoine Flahault
- Institute of Global, Health, Faculty of Medicine, University of Geneva, Switzerland
| |
Collapse
|
36
|
Hoefer D, Ruttmann-Ulmer E, Bonaros N, Hangler H, Grimm M, Müller L. Redo Surgery for Mitral Valve Disease: Is It Really Dangerous? Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
37
|
Pausch J, Gross TMS, Müller L, von Stumm M, Kloth B, Sinning C, Reichenspurner H, Girdauskas E. Improved Long-Term Outcome after Standardized Subvalvular Mitral Valve Repair for Type IIIB Functional Mitral Regurgitation. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Hoefer D, Bonaros N, Holfeld J, Grimm M, Müller L. Functional Prolapse in Barlow's Syndrome: Endoscopic Mitral Valve Repair. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Girdauskas E, Kempfert J, Kuntze T, Holubec T, Krane M, Borger M, Eden M, Bramlage P, Pausch J, Gross TMS, Müller L, Reichenspurner H. Standardized Subannular Repair for Treatment of Secondary Mitral Regurgitation: Initial Results from the Reform-MR Registry. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Zibunas C, Kätelhön A, Meys R, Müller L, Bardow A. Konsequenzen einer CO
2
‐Bepreisung für die chemische Industrie: Erkenntnisse aus einem Bottom‐up‐Modell. CHEM-ING-TECH 2020. [DOI: 10.1002/cite.202055075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C. Zibunas
- RWTH Aachen University Lehrstuhl für Technische Thermodynamik Schinkelstr. 8 52062 Aachen Deutschland
| | - A. Kätelhön
- RWTH Aachen University Lehrstuhl für Technische Thermodynamik Schinkelstr. 8 52062 Aachen Deutschland
| | - R. Meys
- RWTH Aachen University Lehrstuhl für Technische Thermodynamik Schinkelstr. 8 52062 Aachen Deutschland
| | - L. Müller
- RWTH Aachen University Lehrstuhl für Technische Thermodynamik Schinkelstr. 8 52062 Aachen Deutschland
| | - A. Bardow
- RWTH Aachen University Lehrstuhl für Technische Thermodynamik Schinkelstr. 8 52062 Aachen Deutschland
- Forschungszentrum Jülich GmbH Institut für Energie- und Klimaforschung (IEK-10) Wilhelm-Johnen-Straße 52425 Jülich Deutschland
- ETH Zürich Energy & Process Systems Engineering 8092 Zürich Schweiz
| |
Collapse
|
41
|
Meys R, Müller L, Kätelhön A, Suh S, Bardow A. Achieving zero‐carbon emission chemicals and plastics with limited renewable resources. CHEM-ING-TECH 2020. [DOI: 10.1002/cite.202055432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- R. Meys
- RWTH Aachen Institute for Technical Thermodynamics Aachen Germany
| | - L. Müller
- RWTH Aachen Institute for Technical Thermodynamics Aachen Germany
| | - A. Kätelhön
- RWTH Aachen Institute for Technical Thermodynamics Aachen Germany
| | - S. Suh
- University of California Bren School of Environmental Science & Management Santa Barbara USA
| | - André Bardow
- RWTH Aachen Institute for Technical Thermodynamics Aachen Germany
- Forschungszentrum Jülich Institute for Energy and Climate Research (IEK-10) Jülich Germany
- ETH Zürich Energy & Process Systems Engineering Zürich Switzerland
| |
Collapse
|
42
|
Uhlig J, Potenberg J, Semsek D, Stübs P, Fichter C, Köhler A, Müller L, Reiser M, Siebenbach H, Göhler T, Jacobasch L, Kächele V, Timm B, Potthoff K, Marschner N. 457P 1st-line panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
43
|
Müller L, de Rooy D. Groepsbehandeling voor studenten? Graag meer onderzoek! GZ - Psychologie 2020. [PMCID: PMC7450148 DOI: 10.1007/s41480-020-0754-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Richard A, Müller L, Wisniak A, Thiabaud A, Merle T, Dietrich D, Paolotti D, Jeannot E, Flahault A. Grippenet: A New Tool for the Monitoring, Risk-Factor and Vaccination Coverage Analysis of Influenza-Like Illness in Switzerland. Vaccines (Basel) 2020; 8:vaccines8030343. [PMID: 32605076 PMCID: PMC7565003 DOI: 10.3390/vaccines8030343] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 06/16/2020] [Accepted: 06/23/2020] [Indexed: 11/25/2022] Open
Abstract
Implemented in Switzerland in November 2016, Grippenet provides Internet-based participatory surveillance of influenza-like illness (ILI). The aim of this research is to test the feasibility of such a system and its ability to detect risk factors and to assess ILI-related behaviors. Participants filled in a web-based socio-demographic and behavioral questionnaire upon registration, and a weekly symptoms survey during the influenza season. ILI incidence was calculated weekly, and risk factors associated to ILI were analyzed at the end of each season. From November 2016 to May 2019, 1247 participants were included. The crossing of the Sentinel System (Sentinella) epidemic threshold was associated with an increase or decrease of Grippenet ILI incidence, within the same week or earlier. The number of active users varied according to ILI incidence. Factors associated with ILI were: ages 0–4 compared with 5–14 (adjusted odds ratio (AOR) 0.6, 95% confidence interval (CI) 0.19–0.99), 15–29 (AOR 0.29, 95% CI 0.15–0.60), and 65+ (AOR 0.38, 95% CI 0.16–0.93); female sex (male AOR 0.81, 95% CI 0.7–0.95); respiratory allergies (AOR 1.58, 95% CI 1.38–1.96), not being vaccinated (AOR 2.4, 95% CI 1.9–3.04); and self-employment (AOR 1.97, 95% CI 1.33–3.03). Vaccination rates were higher than those of the general population but not high enough to meet the Swiss recommendations. Approximately, 36.2% to 42.5% of users who reported one or more ILIs did not seek medical attention. These results illustrate the potential of Grippenet in complementing Sentinella for ILI monitoring in Switzerland.
Collapse
Affiliation(s)
- Aude Richard
- Institute of Global Health, Faculty of Medicine, University of Geneva, 1202 Geneva, Switzerland; (L.M.); (A.W.); (A.T.); (T.M.); (D.D.); (E.J.); (A.F.)
- Correspondence:
| | - Laura Müller
- Institute of Global Health, Faculty of Medicine, University of Geneva, 1202 Geneva, Switzerland; (L.M.); (A.W.); (A.T.); (T.M.); (D.D.); (E.J.); (A.F.)
| | - Ania Wisniak
- Institute of Global Health, Faculty of Medicine, University of Geneva, 1202 Geneva, Switzerland; (L.M.); (A.W.); (A.T.); (T.M.); (D.D.); (E.J.); (A.F.)
| | - Amaury Thiabaud
- Institute of Global Health, Faculty of Medicine, University of Geneva, 1202 Geneva, Switzerland; (L.M.); (A.W.); (A.T.); (T.M.); (D.D.); (E.J.); (A.F.)
| | - Thibaut Merle
- Institute of Global Health, Faculty of Medicine, University of Geneva, 1202 Geneva, Switzerland; (L.M.); (A.W.); (A.T.); (T.M.); (D.D.); (E.J.); (A.F.)
| | - Damien Dietrich
- Institute of Global Health, Faculty of Medicine, University of Geneva, 1202 Geneva, Switzerland; (L.M.); (A.W.); (A.T.); (T.M.); (D.D.); (E.J.); (A.F.)
- Luxembourg Institute of Health, 1445 Strassen, Luxemburg
| | - Daniela Paolotti
- Institute for Scientific Interchange Foundation, 10126 Torino, Italy;
| | - Emilien Jeannot
- Institute of Global Health, Faculty of Medicine, University of Geneva, 1202 Geneva, Switzerland; (L.M.); (A.W.); (A.T.); (T.M.); (D.D.); (E.J.); (A.F.)
- Addiction Medicine, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, 1004 Lausanne, Switzerland
| | - Antoine Flahault
- Institute of Global Health, Faculty of Medicine, University of Geneva, 1202 Geneva, Switzerland; (L.M.); (A.W.); (A.T.); (T.M.); (D.D.); (E.J.); (A.F.)
| |
Collapse
|
45
|
Müller L, Noseda R, Bertoli R, Bissig M, Ceschi A. Off-label use of quetiapine in nursing homes: Does medical specialty of prescribing physicians play a role? Br J Clin Pharmacol 2020; 86:1444-1445. [PMID: 32100324 DOI: 10.1111/bcp.14232] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Revised: 01/08/2020] [Accepted: 01/18/2020] [Indexed: 11/27/2022] Open
Affiliation(s)
- Laura Müller
- Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Roberta Noseda
- Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Raffaela Bertoli
- Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Marco Bissig
- Hospital Pharmacy, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Alessandro Ceschi
- Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.,Faculty of Biomedical Sciences, University of Southern Switzerland, Lugano, Switzerland
| |
Collapse
|
46
|
Pausch J, Sequeira Gross TM, Müller L, Kloth B, Sinning C, Reichenspurner H, Girdauskas E. Subannular Repair for Functional Mitral Regurgitation Type IIIb in Patients with Ischemic versus Dilated Cardiomyopathy. Thorac Cardiovasc Surg 2020. [DOI: 10.1055/s-0040-1705338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
47
|
Sequeira Gross TM, Pausch J, Müller L, von Stumm M, Sinn M, Lund G, Reichenspurner H, Girdauskas E. Impact of Myocardial Fibrosis on the Left Ventricular Reremodeling after Subannular Repair for Type-IIIb Functional Mitral Regurgitation. Thorac Cardiovasc Surg 2020. [DOI: 10.1055/s-0040-1705339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
48
|
Heinrich K, Heinemann V, Müller L, Büchner-Steudel P, Ettrich T, Stintzing S, Schulz C. Multicenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Grünwald V, Grüllich C, Ivanyi P, Wirth M, Staib P, Schostak M, Dargatz P, Müller L, Metz M, Bergmann L, Welslau M, Schütt P, Rafiyan MR, Hellmis E, Hinke A, Meiler J, Kretz T, Loidl W, Flörcken A, Steiner T. A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Wolfe CE, Wood DM, Dines A, Whatley BP, Yates C, Heyerdahl F, Hovda KE, Giraudon I, Dargan PI, Anseeuw K, Badaras R, Bonnici J, Brvar M, Caganova B, Ceschi A, Eyer F, Galicia M, Geith S, Gillebeert J, Grenc D, Gorozia K, Jaffal K, Jürgens G, Kabata PM, Kennedy I, Konstari J, Kutubidze S, Laubner G, Liakoni E, Liechti ME, Lyphout C, Mégarbane B, Miró Ò, Moughty A, Müller L, O'Connor N, Paasma R, Perez JO, Perminas M, Persett PS, Põld K, Puiguriguer J, Radenkova-Saeva J, Rulisek J, Schmid Y, Scholz I, Sopirala R, Surkus J, Toth I, Vallersnes OM, Vigorita F, Waldman W, Waring WS, Zacharov S. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set. Neurotoxicology 2019; 73:183-187. [DOI: 10.1016/j.neuro.2019.04.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Revised: 04/04/2019] [Accepted: 04/04/2019] [Indexed: 10/27/2022]
|